QuantiFERON CMV Test and CMV Serostatus in Lung Transplant: Stratification Risk for Infection, Chronic and Acute Allograft Rejection

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2024 Aug 29

PMID 39205225

Authors

Paolo Solidoro

Federico Sciarrone

Francesca Sidoti

Filippo Patrucco

Elisa Zanotto

Massimo Boffini

Rocco Francesco Rinaldo

Alessandro Bondi

Carlo Albera

Antonio Curtoni

Cristina Costa

Affiliations

Soon will be listed here.

Abstract

The QuantiFERON CMV (QCMV) test evaluates specific adaptive immune system activity against CMV by measuring IFN-γ released by activated CD8+ T lymphocytes. We aimed to evaluate the QCMV test as a predictive tool for CMV manifestations and acute or chronic lung allograft rejection (AR and CLAD) in lung transplant (LTx) patients. A total of 73 patients were divided into four groups based on donor and recipient (D/R) serology for CMV and QCMV assay: group A low-risk for CMV infection and disease (D-/R-); group B and C at intermediate-risk (R+), group B with non-reactive QCMV and group C with reactive QCMV; group D at high-risk (D+/R-). Group D patients experienced higher viral replication; no differences were observed among R+ patients of groups B and C. D+/R- patients had a higher number of AR events and group C presented a lower incidence of AR. Prevalence of CLAD at 24 months was higher in group B with a higher risk of CLAD development (OR 6.33). The QCMV test allows us to identify R+ non-reactive QCMV population as the most exposed to onset of CLAD. This population had a higher, although non-significant, susceptibility to AR compared to the R+ population with reactive QCMV.

Citing Articles

QuantiFERON Monitor Test as a Potential Tool for Stratifying Patients by Infection Risk and Tailoring Follow-Up Care in Lung Transplant Recipients: A Single-Center Retrospective Experience.

Solidoro P, Curtoni A, Patrucco F, Russo E, Sidoti F, Piccinini G Microorganisms. 2025; 13(2).

PMID: 40005684 PMC: 11858317. DOI: 10.3390/microorganisms13020316.

References

Kumar D, Mian M, Singer L, Humar A . An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation. Am J Transplant. 2017; 17(9):2468-2473. DOI: 10.1111/ajt.14347. View

Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi M . Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2012; 56(6):817-24. DOI: 10.1093/cid/cis993. View

Gardiner B, Lee S, Robertson A, Cristiano Y, Snell G, Morrissey C . Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients. J Heart Lung Transplant. 2022; 41(9):1258-1267. DOI: 10.1016/j.healun.2022.05.004. View

Snyder L, Finlen-Copeland C, Turbyfill W, Howell D, Willner D, Palmer S . Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010; 181(12):1391-6. PMC: 2894412. DOI: 10.1164/rccm.200911-1786OC. View

Verleden G, Glanville A, Lease E, Fisher A, Calabrese F, Corris P . Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019; 38(5):493-503. DOI: 10.1016/j.healun.2019.03.009. View

Balthesen M, Messerle M, Reddehase M . Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol. 1993; 67(9):5360-6. PMC: 237936. DOI: 10.1128/JVI.67.9.5360-5366.1993. View

Solidoro P, Libertucci D, Delsedime L, Ruffini E, Bosco M, Costa C . Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections. Transplant Proc. 2008; 40(6):2013-4. DOI: 10.1016/j.transproceed.2008.05.028. View

Weigt S, Elashoff R, Keane M, Strieter R, Gomperts B, Xue Y . Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant. 2008; 8(7):1512-22. PMC: 2760345. DOI: 10.1111/j.1600-6143.2008.02280.x. View

Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P . Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant. 2012; 12(8):2172-80. DOI: 10.1111/j.1600-6143.2012.04076.x. View

10.

Tarasewicz A, Debska-Slizien A, Rutkowski B . Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients. Transplant Proc. 2016; 48(5):1650-3. DOI: 10.1016/j.transproceed.2016.01.046. View

11.

Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J . Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009; 9(5):1214-22. DOI: 10.1111/j.1600-6143.2009.02618.x. View

12.

Estenne M, Maurer J, Boehler A, Egan J, Frost A, Hertz M . Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002; 21(3):297-310. DOI: 10.1016/s1053-2498(02)00398-4. View

13.

Solidoro P, Patrucco F, Libertucci D, Verri G, Sidoti F, Curtoni A . Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis. Ther Adv Respir Dis. 2019; 13:1753466619878555. PMC: 6769221. DOI: 10.1177/1753466619878555. View

14.

Cantisan S, Lara R, Montejo M, Redel J, Rodriguez-Benot A, Gutierrez-Aroca J . Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013; 13(3):738-45. DOI: 10.1111/ajt.12049. View

15.

Westall G, Cristiano Y, Levvey B, Whitford H, Paraskeva M, Paul E . A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation. Transplantation. 2018; 103(5):1005-1013. DOI: 10.1097/TP.0000000000002454. View

16.

Wreghitt T . Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989; 23 Suppl E:49-60. DOI: 10.1093/jac/23.suppl_e.49. View

17.

Johansson I, Martensson G, Nystrom U, Nasic S, Andersson R . Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis. 2013; 13:582. PMC: 3878887. DOI: 10.1186/1471-2334-13-582. View

18.

Paraskeva M, Bailey M, Levvey B, Griffiths A, Kotsimbos T, Williams T . Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant. 2011; 11(10):2190-6. DOI: 10.1111/j.1600-6143.2011.03663.x. View

19.

Kotton C, Kumar D, Caliendo A, Huprikar S, Chou S, Danziger-Isakov L . The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018; 102(6):900-931. DOI: 10.1097/TP.0000000000002191. View

20.

Costa C, Astegiano S, Terlizzi M, Sidoti F, Curtoni A, Solidoro P . Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc. 2011; 43(4):1159-61. DOI: 10.1016/j.transproceed.2011.03.024. View